WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. The meeting will be held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, TX.(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )
These studies highlight Eisai's current and ongoing clinical research efforts with Halaven® (eribulin mesylate) Injection, reinforcing the company's commitment to the breast cancer community. Additionally, Phase III study results of the head-to-head study of eribulin vs. capecitabine will be highlighted as part of a SABCS-sponsored news conference to be held on December 7, 2012.
"As part of our human health care mission we strive to better understand the needs of patients and their families to help increase the benefits that healthcare provides," said Kenichi Nomoto, Ph.D., President, Oncology Product Creation Unit at Eisai. "Our continued work to further understand the clinical profile of eribulin underscores our commitment to this important mission."
The following Eisai abstracts are accepted for presentation at this year's San Antonio Breast Cancer Symposium:ProductAbstract NameEribulin Mesylate
S6-6A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
Oral PresentationEribulin Mesylate
P1-12-02Results of a Phase II, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer
Poster SessionEribulin Mesylate
P5-20-04Eribulin mesylate + tras
|SOURCE Eisai Inc.|
Copyright©2012 PR Newswire.
All rights reserved